PRESTIGE CONSUMER HEALTHCARE (PBH) Stock News
NYSE:PBH - New York Stock Exchange, Inc. - US74112D1019 - Common Stock - Currency: USD
PBH Latest News, Press Relases and Analysis
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 09, 2025 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside...
Prestige Consumer Healthcare Inc. to Present at the Oppenheimer Annual Consumer Growth and E-Commerce Conference
PEN Stock Rises Following the Launch of Ruby XL System
Penumbra launches FDA-cleared Ruby XL System to bring advanced coil technology to high-flow embolization procedures.
PBH vs. SYK: Which Stock Is the Better Value Option?
PBH vs. SYK: Which Stock Is the Better Value Option?
Mentions: SYK
PBH vs. ESLOY: Which Stock Should Value Investors Buy Now?
PBH vs. ESLOY: Which Stock Is the Better Value Option?
Is it Apt to Retain Omnicell Stock in Your Portfolio Now?
OMCL stays on investors' radar due to its strong 2025 growth targets with automation and tech services, but faces margin risks from macro and competitive headwinds.
Here's Why You Should Retain ICLR Stock in Your Portfolio Now
Investors remain optimistic about ICON, driven by its commitment to enhance clinical delivery by integrating AI and impressive strategic pacts.
LH Stock Rises Following the Expansion of Precision Oncology Portfolio
Labcorp expands its precision oncology lineup with new cancer tests and a global diagnostic tool.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Abbott Benefits From Libre & Biosimilars Amid FX, Cost Headwinds
ABT sees a 21.6% jump in CGM sales and growing global diagnostics demand, while FX and macro pressure temper its outlook.
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Thermo Fisher Launches New Spectral Flow Cytometer: Stock to Gain?
TMO unveils spectral-enabled Attune Xenith Flow Cytometer to streamline workflows and boost research accuracy.
Bruker Stock to Gain From the Launch of MOVE-T Liquid Dairy Analyzer
BRKR unveils the MOVE-T analyzer to boost quality and efficiency in the dairy industry, setting new standards for precision and reliability.
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?
TECH is gaining ground in cell and gene therapy, and with Ella, while navigating macro hurdles. Is it the right fit for your portfolio today?
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Prestige Consumer Gains 35.7% in a Year: What's Driving the Stock?
PBH stock jumps on the back of brand strength, e-commerce gains and smart acquisitions despite tariff and foreign exchange headwinds.
TMO Stock Set to Gain From the Launch of New Narcotic Analyzers
Thermo Fisher launches new TruNarc analyzers to help law enforcement quickly detect 1,200+ substances, boosting field safety and drug interdiction efforts.
Should You Retain Henry Schein Stock in Your Portfolio Right Now?
Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.
Insulet Gains 78.5% in a Year: What's Driving the Stock?
PODD's shares rise on the back of Omnipod 5's growth, global expansion, and strong Q1 2025 gains despite rising operating costs and macro headwinds.
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock
EW's new late-breaking clinical data shows early intervention in AS may slash significant costs and improve patient outcomes.
Penumbra Rallies 35.9% in a Year: What's Driving the Stock?
PEN has shown notable strength over the past year, driven by the performance of its core U.S. thrombectomy business. Solid international prospects instill optimism.
Should Tandem Diabetes Stock Stay in Your Portfolio Now?
Investors remain optimistic about TNDM, courtesy of its strong t:slim X2 performance and breakthrough innovations.
AST Business Growth & Strategic Acquisitions Support STERIS Stock
STE frequently engages in strategic acquisitions and joint ventures to optimize its portfolio of businesses.
What's Driving Quest Diagnostics Stock's 25.6% Rally in a Year?
DGX has shown notable strength in the past year, driven by robust core performance and contributions from acquisitions.
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase
PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.
Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Prestige Consumer Healthcare (PBH) Tops Q4 Earnings and Revenue Estimates
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 1.54% and 2.62%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: MDT
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
UPDATED: Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal...
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
Revenue of $296.5 million in Q4 and $1,137.8 million in fiscal 2025Organic revenue grew 7.9% in Q4 and 1.2% in fiscal 2025Diluted EPS of $4.29 in fiscal...
Prestige Consumer Healthcare Inc. Reports Record Fiscal 2025 Revenue and Earnings
Insights Into Prestige Consumer Healthcare (PBH) Q4: Wall Street Projections for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Prestige Consumer Healthcare (PBH) Reports Next Week: Wall Street Expects Earnings Growth
Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: PRGO
EMEA Growth & Product Launches to Support Boston Scientific Stock
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.